Lenvatinib
Back to searchMolecule Structure
Scientific Name
Lenvatinib
Description of the Drug
Lenvatinib is a receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09078
http://www.drugbank.ca/drugs/DB09078
Brand Name(s)
Kisplyx, Lenvima
Company Owner(s)
Eisai Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Vascular endothelial growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095227 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL864638 | ||
| PharmGKB | PA166153472 | ||
| Human Metabolome Database | HMDB0254011 | ||
| DrugBank | DB09078 | ||
| PubChem: Thomson Pharma | 14782907 | ||
| PubChem | 9823820 | ||
| LINCS | LSM-45581 | ||
| Nikkaji | J2.624.265G | ||
| PDBe | LEV | ||
| BindingDB | 50331094 | ||
| EPA CompTox Dashboard | DTXSID50194605 | ||
| DrugCentral | 4942 | ||
| ChemicalBook | CB12484883 | ||
| Guide to Pharmacology | 7426 | ||
| rxnorm | LENVATINIB MESYLATE | LENVATINIB | LENVIMA |
| ChEBI | 85994 | ||
| ZINC | ZINC000003816292 |
